Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224585 · ClinicalTrials.gov registry record · Phase 2
Treatment of Acute Pericarditis With Anakinra
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03224585 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 5 participants.
The verdict
NCT03224585, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days. 1. to determine the efficacy of anakinra with respect to chest pain resolution 2. to determine the safety of anakinra with respect to adverse drug events
Interventions
- DRUG Placebo
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-05-11 |
| Est. Completion | 2020-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224585
The ClinicalTrials.gov registry entry for NCT03224585 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03224585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03224585 about?
NCT03224585 is a clinical study titled "Treatment of Acute Pericarditis With Anakinra". The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days. 1. to determine the efficacy of anakinra with respect to chest pain resolution 2. to determine the safety of a...
What is the current status of trial NCT03224585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-05-11. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT03224585?
The interventions under investigation include: Placebo (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT03224585?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.